Summary

This article discusses results from a study that compared double- with triple-dose antiplatelet therapy (DAPT vs TAPT) in acute coronary syndrome patients who were undergoing percutaneous coronary intervention, which showed no difference in net clinical outcomes between the two treatment regimens after 1 month.